Family history and herpes zoster risk in the era of shingles vaccination

Journal of Clinical Virology

Volumn 52, Issue 4, 2011, Pages 344-348

  Hernandez, Paul O ^a   Javed, Saba ^b   Mendoza, Natalia ^c   Lapolla, Whitney ^c   Hicks, Lindsey D ^d   Tyring, Stephen K ^c,d  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c CENTER FOR CLINICAL STUDIES   (United States)

^d University of Texas Health Science Center at Houston   (United States)

Author keywords

Herpes zoster; HZ; Shingles; Vaccine; Varicella zoster virus; VZV

Indexed keywords

VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SCHOOL CHILD; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FAMILY HEALTH; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; RISK ASSESSMENT; VACCINATION; YOUNG ADULT;

EID: 82755197731     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.08.014     Document Type: Article

References (26)

1. Creed R., Satyaprakash A., Tyring S.K. Varicella-zoster virus. Mucocutaneous manifestations of viral diseases 2010, 98-122. Informa Healthcare, Cornwall. S.K. Tyring, A. Yen Moore, O. Lupi (Eds.).
2. Donahue J.G., Belongia E.A. The looming rash of herpes zoster and the challenge of adult immunization. Ann Intern Med 2010, 152:609-611.
3. Gershon A.A., Gershon M.D., Breuer J., Levin M.J., Oaklander A.L., Griffiths P.D. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010, 48(Suppl. 1):S2-S7.
4. Hicks L.D., Cook-Norris R.H., Mendoza N., Madkan V., Arora A., Tyring S.K. Family history as a risk factor for herpes zoster: a case-control study. Arch Dermatol 2008, 144:603-608.
5. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352:2271-2284.
6. Ebede T.L., Zippin J.H. Varicella virus and the herpes zoster vaccine. A review of Zostavax and the new AFIP recommendations. J Drugs Dermatol 2008, 7:1173-1176.
7. Voelker R. FDA expands age range for shingles vaccine. JAMA 2011, 305:1526.
8. Gatti A., Pica F., Boccia M.T., De Antoni F., Sabato A.F., Volpi A. No evidence of family history as a risk factor for herpes zoster in patients with post-herpetic neuralgia. J Med Virol 2010, 82:1007-1011.
9. Drolet M., Brisson M., Schmader K., Levin M., Johnson R., Oxman M., et al. Predictors of postherpetic neuralgia among patients with herpes zoster: a prospective study. J Pain 2010, 11:1211-1221.
10. Johnson R.W. Herpes zoster and postherpetic neuralgia. Expert Rev Vaccines 2010, 9:21-26.
11. Haanpaa M., Nurmikko T., Hurme M. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster. Scand J Infect Dis 2002, 34:112-114.
12. Cho J.W., Shin D.H., Lee K.S. Polymorphism of the IL-10 gene is associated with susceptibility to herpes zoster in Korea. J Dermatol Sci 2007, 45:213-215.
13. Wozniak M.A., Shipley S.J., Dobson C.B., Parker S.P., Scott F.T., Leedham-Green M., et al. Does apolipoprotein E determine outcome of infection by varicella zoster virus and by Epstein Barr virus?. Eur J Hum Genet 2007, 15:672-678.
14. Leung J., Harpaz R., Molinari N.A., Jumaan A., Zhou F. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin Infect Dis 2011, 52:332-340.
15. Thomas S.L., Wheeler J.G., Hall A.J. Micronutrient intake and the risk of herpes zoster: a case control study. Int J Epidemiol 2006, 35:307-314.
16. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82:1341-1349.
17. Insinga R.P., Itzler R.F., Pellissier J.M., Saddier P., Nikas A.A. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med 2005, 20:748-753.
18. Hope-Simpson R.E. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-20.
19. Thomas S.L., Wheeler J.G., Hall A.J. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360:678-682.
20. Thomas S.L., Hall A.J. What does epidemiology tell us about risk factors for herpes zoster?. Lancet Infect Dis 2004, 4:26-33.
21. Brisson M., Gay N.J., Edmunds W.J., Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20:2500-2507.
22. Schuette M.C., Hethcote H.W. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 1999, 61:1031-1064.
23. Edmunds W.J., Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. J Infect 2002, 44:211-219.
24. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Publ Health 2005, 5:68.
25. Tseng H.F., Smith N., Harpaz R., Bialek S.R., Sy L.S., Jacobsen S.J. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011, 305:160-166.
26. Yawn B.P., Wollan P.C., Kurland M.J., St.Sauver J.L., Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011, 86:88-93.